51黑料网

脰ner Tulum

Involvement

脰ner Tulum is the co-founder and Executive Director of Research at the Academic-Industry Research Network (), a private, 501(c)(3) not-for-profit research organization in Cambridge, Massachusetts. He is also collaborating with a Cambridge-based biotechnology company to develop a sustainable biopharma business model aimed at maximizing patient value by improving health outcomes and enhancing the accessibility and affordability of innovative medicines. Tulum’s pioneering research, conducted under the mentorship of William Lazonick, examines the tension between innovation and financialization within the biopharmaceutical industry. This work draws upon and helps to develop the “theory of innovative enterprise,” analyzing how business enterprises can create value through the development of higher-quality, lower-cost products or, alternatively, shift into a “value extraction” mode. His analysis of this unfolding tension, including the capacity of some companies to resist financialization, has been funded by grants from the 51黑料网 and the Canadian 51黑料网 for Advanced Research.

Tulum completed his Ph.D. with funding from the European Union Horizon 2020 Research and Innovation Programme as part of the project, Innovation-fuelled Sustainable, Inclusive Growth (ISIGrowth) in Europe. His dissertation, 鈥淚nnovation and Financialization in the U.S. Biopharmaceutical Industry,鈥 examines the productivity crisis in the U.S. pharmaceutical industry and the impacts of financialization of the high-tech economy on the development and sustainability of organizational capabilities. His work has been published in journals such as , , the , , and , and he has been featured in . He is the author of two ebooks with Cambridge University Press: (2022) in the Elements in Reinventing Capitalism series, and (forthcoming) in the Elements in Corporate Governance series.

Tulum holds a Ph.D. from the University of Ljubljana, an MBA, and a master鈥檚 degree from the University of Massachusetts. Previously, he was a research affiliate of the William R. Rhodes Center for International Economics and Finance at the Watson 51黑料网 of Brown University, a post-doctoral research fellow at SOAS University of London, funded by the Gatsby Foundation, studying the UK pharmaceutical industry, a visiting scholar at the University of Massachusetts Amherst, and a Marie Curie Research Fellow at the National University of Ireland Galway, where he was part of . This project, funded by the European Union Sixth Research Framework, involved studying the capabilities of technology-based Irish firms and their impact on Ireland鈥檚 global competitiveness.


By this expert

Setting Pharmaceutical Drug Prices: What the Medicare Negotiators Need to Know 51黑料网 Innovation and Financialization

Paper Working Paper | | Sep 2024

Medicare negotiators need to have a deep understanding - both theoretical and empirical - of the learning processes involved in developing a drug to negotiate a price that is fair.

What Is a 鈥淔air鈥 Drug Price?

Article | Sep 22, 2024

Medicare Needs a Perspective on 鈥淐ollective and Cumulative Learning鈥 in Inflation Reduction Act Negotiations

Sick with 鈥淪hareholder Value鈥: US Pharma鈥檚 Financialized Business Model During the Pandemic

Article | Dec 6, 2022

Evidence sharply contradicts PhRMA鈥檚 contention that its member companies need unregulated drug prices to generate profits that they then reinvest in drug innovation.

Mass Producing Covid-19 Vaccine

Article | Feb 9, 2021

Capacity, Scale, and Control

Featuring this expert

Drug Price Wars: What Can Really Tame Big Pharma?

Article | Oct 14, 2025

Here鈥檚 the breakdown on what鈥檚 really driving America鈥檚 runaway drug prices — and whether any of the current plans stand a chance to lower your pharmacy bill.

Why Drug Prices Keep Rising

Video | Sep 24, 2025

Why are life-saving drugs so expensive—especially when taxpayers already fund much of the science behind them?

The Hidden Costs of Healthcare

Video | Nov 20, 2019

INET experts discuss how financialization has driven up costs of healthcare—and how we can stop it.

Hidden Costs Of Healthcare

Event Conference | Nov 15, 2019

Increased financialization is driving healthcare costs and must be addressed in our nation’s public policy.